Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate.
about
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancerTargeting the androgen receptor in prostate and breast cancer: several new agents in developmentThe ETS family of oncogenic transcription factors in solid tumours.Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer.Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.Current advances in intratumoral androgen metabolism in castration-resistant prostate cancer.Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study.Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer.Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.The evolution of chemotherapy for the treatment of prostate cancer.Precision Medicine and Men's Health.SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.Liquid biopsies and plasma DNA: paving the way for personalized medicine in metastatic castration-resistant prostate cancer.Diagnostic Gleason score and castration-resistant prostate cancer.Prioritizing precision medicine for prostate cancer
P2860
Q26796568-A1B44D0B-3E48-411D-BCE6-3B48066243BBQ27009424-5AF9DD23-DC4D-4ACD-B29F-B7557DBC7A18Q34555986-92111A76-F4BD-4728-AC1F-F29E90F5E474Q35690915-79846802-1BA5-4989-89A5-DDB886107CE5Q35938840-A43F73C8-7427-4373-808B-52941C1E3D06Q36407003-C345195A-D70C-45CD-9BDE-D2A7365DDE3CQ36970812-4B95FF23-CAB1-43FF-98C0-7E085F08A43FQ37688197-0488222B-2734-45D5-AB72-98CAB8979C86Q38618888-F329F0F5-19E0-49E5-9612-DEC4FC802432Q38804089-1D788FBE-17C3-4380-BE66-B642F220E772Q38994718-9F13BB78-5681-49B3-9EA2-F093D3AA8115Q41867950-12BC9936-B496-4345-9847-354BFD384421Q45943517-E0137357-BFA6-4859-B8F7-4C0EE87E8D52Q47151829-69E3FD11-560B-4D0F-9268-0B23E5E13426Q48310246-07ED73F1-1058-48BF-ABD7-475A210B40EDQ51549809-40AFF454-8CF4-4ADB-A690-1B043A49C719Q53741855-B2706E6A-7BAD-44BF-8FA1-D17C84E3BDF4Q53789514-BC5E906D-6BE4-46E1-A88C-21202AF645F9Q57693858-89194862-3BAC-421C-83F4-5B5EEF7F1738
P2860
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Improvements in Radiographic P ...... ated with Abiraterone Acetate.
@en
type
label
Improvements in Radiographic P ...... ated with Abiraterone Acetate.
@en
prefLabel
Improvements in Radiographic P ...... ated with Abiraterone Acetate.
@en
P2093
P2860
P50
P1476
Improvements in Radiographic P ...... ated with Abiraterone Acetate.
@en
P2093
Alfons J M van den Eertwegh
Arturo Molina
Charles J Ryan
Christopher J Logothetis
Deborah S Ricci
Dirk Schrijvers
Howard I Scher
Johann S de Bono
Kathy Zelinsky
Som D Mukherjee
P2860
P304
P356
10.1158/1078-0432.CCR-14-1961
P407
P577
2015-01-15T00:00:00Z